25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives

Abstract

In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist®), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives.FundingBayer HealthCare.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-015-0275-4) contains supplementary material, which is available to authorized users.

Ultrasound-guided percutaneous microwave ablation for benign breast lesions: evaluated by contrast-enhanced ultrasound combined with magnetic resonance imaging

“…Breast MRI is the most sensitive examination for breast tumor detection and it can be used to detect the spatial relationship between the lesion and the surrounding tissue, the spatial distribution of lesional blood flow as well (14)(15)(16)(17)(18). What's more, MRI can be used to assess tissue necrosis after ablation by administrating contrast agent (19,20). So MRI is suitable for evaluating the efficacy of MWA.…”

Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study

“…Approximately 30 million contrast-enhanced MRIs are performed every year, with an estimated 300 million administered thus far. 1 In multiple sclerosis, GBCAs play a key role in detecting disease activity. Gadolinium has paramagnetic properties that shorten the T1 relaxation in tissues, resulting in an increased signal on T1-weighted imaging.…”

Tunable and noncytotoxic PET/SPECT-MRI multimodality imaging probes using colloidally stable ligand-free superparamagnetic iron oxide nanoparticles

“…Iron oxide magnetic nanoparticles, due to their inherent magnetic properties and feasibility to produce iron oxide cores, are the most common negative (T2 weighted) contrast agents and have been widely applied to in vitro and in vivo studies. [8][9][10][11][12] Among the dual-modality approaches, positron emission tomography/single-photon emission computed tomography (PET/SPECT)-MRI technologies offer high spatial resolution (~50 μm), 13 the best soft tissue contrast, the highest sensitivity, and detection limit. 14 The most common radionuclide probes applied as radiotracers or therapeutic agents in preclinical and clinical practice are 18 F, 64 Cu, 67 Ga, 68 Ga, 89 Zr, 90 Y, 124 I, 99m Tc, 111 In, and 177 Lu.…”

“…Recently, systemic fibrosis was detected in clinical patients who had previously undergone administration of imaging contrast agents for MRI scans. 9,20,21 This side effect is suggested to be associated with the loss of toxic metal ions from the contrast agents. 20 In March 2015, the US Food and Drug Administration issued a report warning about the application of Feraheme (AMAG Pharmaceuticals, Lexington, MA, USA), an iron oxide-based product, in the treatment of anemia due to a number of reported serious side effects in patients.…”